Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET

NCT02446405 is registered in ClinicalTrials.gov with University of Sydney as lead sponsor.

NCT NCT02446405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02446405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
Lead sponsor
University of Sydney
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 31, 2014
Completion date
June 30, 2027
Enrollment
1,125 (actual)
Sites
82

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms